Turnstone Biologics (TSBX)

• Market cap: $7.38M
• 1 day: 0.82%
• 5 days: -5.06%
• 1 month: -22.00%
• 3 months: -30.65%
• 6 months: -37.88%
• Year to date: -40.65%
• 1 year: -89.61%
• 5 years: -97.10%
• 10 years: -97.10%
• Sector: Healthcare
• Industry: Biotechnology

About: Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Employees: 14

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

17% more funds holding

Funds holding: 24 [Q3] → 28 (+4) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

1.5% less ownership

Funds ownership: 49.47% [Q3] → 47.97% (-1.5%) [Q4]

14% less capital invested

Capital invested by funds: $6.37M [Q3] → $5.51M (-$864K) [Q4]